Journal of Clinical Oncology, Vol 19, Issue 12
(June), 2001: 3058-3065
© 2001 American Society for Clinical Oncology
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
By Wolfgang A. Weber,
Katja Ott,
Karen Becker,
Hans-Joachim Dittler,
Hermann Helmberger,
Norbert E. Avril,
Günther Meisetschläger,
Raymonde Busch,
Jörg-Rüdiger Siewert,
Markus Schwaiger,
Ulrich Fink
From the Departments of Nuclear Medicine, Surgery, Pathology, Radiology, and Medical Statistics, Technische Universität München, München, Germany.
Address reprint requests to Wolfgang A. Weber, MD, Nuklearmedizinische Klinik, Klinikum Rechts der Isar, Ismaningerstraße 22, 81675 München, Germany; email: w.weber{at}lrz.tum.de
PURPOSE: Preoperative chemotherapy in patients with gastroesophageal cancer is hampered by the lack of reliable predictors of tumor response. This study evaluates whether positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may predict response early in the course of therapy.
PATIENTS AND METHODS: Forty consecutive patients with locally advanced adenocarcinomas of the esophagogastric junction were studied by FDG-PET at baseline and 14 days after initiation of cisplatin-based polychemotherapy. Clinical response (reduction of tumor length and wall thickness by > 50%) was evaluated after 3 months of therapy using endoscopy and standard imaging techniques. Patients with potentially resectable tumors underwent surgery, and tumor regression was assessed histopathologically.
RESULTS: The reduction of tumor FDG uptake (mean ± 1 SD) after 14 days of therapy was significantly different between responding (-54% ± 17%) and nonresponding tumors (-15% ± 21%). Optimal differentiation was achieved by a cutoff value of 35% reduction of initial FDG uptake. Applying this cutoff value as a criterion for a metabolic response predicted clinical response with a sensitivity and specificity of 93% (14 of 15 patients) and 95% (21 of 22), respectively. Histopathologically complete or subtotal tumor regression was achieved in 53% (eight of 15) of the patients with a metabolic response but only in 5% (one of 22) of the patients without a metabolic response. Patients without a metabolic response were also characterized by significantly shorter time to progression/recurrence (P = .01) and shorter overall survival (P = .04).
CONCLUSION: PET imaging may differentiate responding and nonresponding tumors early in the course of therapy. By avoiding ineffective and potentially harmful treatment, this may markedly facilitate the use of preoperative therapy, especially in patients with potentially resectable tumors.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. Bystrom, A. Berglund, U. Garske, H. Jacobsson, A. Sundin, P. Nygren, J.-E. Frodin, and B. Glimelius
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
Ann. Onc.,
June 1, 2009;
20(6):
1057 - 1061.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
122S - 150S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Krause, K. Herrmann, H. Wieder, and C. M. zum Buschenfelde
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
89S - 96S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Benz, J. Czernin, M. S. Allen-Auerbach, W. D. Tap, S. M. Dry, D. Elashoff, K. Chow, V. Evilevitch, J. J. Eckardt, M. E. Phelps, et al.
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas
Clin. Cancer Res.,
April 15, 2009;
15(8):
2856 - 2863.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Allen-Auerbach and W. A. Weber
Measuring Response with FDG-PET: Methodological Aspects
Oncologist,
April 1, 2009;
14(4):
369 - 377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Kim, H. Y. Kim, K. W. Lee, and M. S. Kim
Multimodality Assessment of Esophageal Cancer: Preoperative Staging and Monitoring of Response to Therapy
RadioGraphics,
March 1, 2009;
29(2):
403 - 421.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al.
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose
J. Clin. Oncol.,
February 1, 2009;
27(4):
535 - 541.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K R Fareed, P Kaye, I N Soomro, M Ilyas, S Martin, S L Parsons, and S Madhusudan
Biomarkers of response to therapy in oesophago-gastric cancer
Gut,
January 1, 2009;
58(1):
127 - 143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Langer, K. Ott, K. Specht, K. Becker, F. Lordick, M. Burian, K. Herrmann, A. Schrattenholz, M. A. Cahill, M. Schwaiger, et al.
Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response
Clin. Cancer Res.,
December 15, 2008;
14(24):
8279 - 8287.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Barbour, M. Jones, M. Gonen, D. C. Gotley, J. Thomas, D. B. Thomson, B. Burmeister, and B. M. Smithers
Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response
Ann. Surg. Oncol.,
October 1, 2008;
15(10):
2894 - 2902.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Higuchi, T. Yasuda, M. Yano, Y. Doki, H. Miyata, M. Tatsumi, H. Fukunaga, S. Takiguchi, Y. Fujiwara, J. Hatazawa, et al.
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma
J. Thorac. Cardiovasc. Surg.,
July 1, 2008;
136(1):
205 - 212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber
Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors
J. Nucl. Med.,
July 1, 2008;
49(7):
1038 - 1046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med.,
June 1, 2008;
49(Suppl_2):
43S - 63S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. I. Khushalani
Cancer of the Esophagus and Stomach
Mayo Clin. Proc.,
June 1, 2008;
83(6):
712 - 722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ott, K. Herrmann, F. Lordick, H. Wieder, W. A. Weber, K. Becker, A. K. Buck, M. Dobritz, U. Fink, K. Ulm, et al.
Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study
Clin. Cancer Res.,
April 1, 2008;
14(7):
2012 - 2018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-L. Song, J.-J. Liu, G. Huang, Z.-H. Wang, Y.-Y. Song, X.-G. Sun, and T. Chen
Changes in 18F-FDG Uptake Within Minutes After Chemotherapy in a Rabbit VX2 Tumor Model
J. Nucl. Med.,
February 1, 2008;
49(2):
303 - 309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Ilson
Combined Modality Therapy for Gastric, Esophageal, and Gastroesophageal Junction Cancers
ASCO Educational Book,
January 1, 2008;
2008(1):
177 - 182.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. Schuster, H.-J. Wester, J. R. Siewert, et al.
Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis
J. Nucl. Med.,
December 1, 2007;
48(12):
1945 - 1950.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA,
November 21, 2007;
298(19):
2289 - 2295.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology,
November 1, 2007;
245(2):
333 - 356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Bruzzi, R. F. Munden, M. T. Truong, E. M. Marom, B. S. Sabloff, G. W. Gladish, R. B. Iyer, T.-S. Pan, H. A. Macapinlac, and J. J. Erasmus
PET/CT of Esophageal Cancer: Its Role in Clinical Management
RadioGraphics,
November 1, 2007;
27(6):
1635 - 1652.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
J. Nucl. Med.,
September 1, 2007;
48(9):
1449 - 1458.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F.-M. S. Kong, K. A. Frey, L. E. Quint, R. K. T. Haken, J. A. Hayman, M. Kessler, I. J. Chetty, D. Normolle, A. Eisbruch, and T. S. Lawrence
A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer
J. Clin. Oncol.,
July 20, 2007;
25(21):
3116 - 3123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al.
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
June 15, 2007;
13(12):
3552 - 3558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Ilson
Surgery After Primary Chemoradiotherapy in Squamous Cancer of the Esophagus: Is the Photon Mightier Than the Sword?
J. Clin. Oncol.,
April 1, 2007;
25(10):
1155 - 1156.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ott, W. A. Weber, F. Lordick, K. Becker, R. Busch, K. Herrmann, H. Wieder, U. Fink, M. Schwaiger, and J.-R. Siewert
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
J. Clin. Oncol.,
October 10, 2006;
24(29):
4692 - 4698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Apisarnthanarax, M. M. Alauddin, F. Mourtada, H. Ariga, U. Raju, O. Mawlawi, D. Han, W. G. Bornmann, J. A. Ajani, L. Milas, et al.
Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3'-Deoxy-3'-3H-Fluorothymidine Using Preclinical Tumor Models
Clin. Cancer Res.,
August 1, 2006;
12(15):
4590 - 4597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Clin. Cancer Res.,
July 15, 2006;
12(14):
4232 - 4236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol.,
July 10, 2006;
24(20):
3282 - 3292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Beer, H. A. Wieder, F. Lordick, K. Ott, M. Fischer, K. Becker, J. Stollfuss, and E. J. Rummeny
Adenocarcinomas of Esophagogastric Junction: Multi-Detector Row CT to Evaluate Early Response to Neoadjuvant Chemotherapy
Radiology,
May 1, 2006;
239(2):
472 - 480.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Juweid and B. D. Cheson
Positron-Emission Tomography and Assessment of Cancer Therapy
N. Engl. J. Med.,
February 2, 2006;
354(5):
496 - 507.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen
Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation
Am. J. Roentgenol.,
February 1, 2006;
186(2):
308 - 319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks
Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery
J. Nucl. Med.,
January 1, 2006;
47(1):
14 - 22.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P J Ell
The contribution of PET/CT to improved patient management
Br. J. Radiol.,
January 1, 2006;
79(937):
32 - 36.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Lim, M. J. Yun, M.-J. Kim, W. J. Hyung, M.-S. Park, J.-Y. Choi, T.-S. Kim, J. D. Lee, S. H. Noh, and K. W. Kim
CT and PET in Stomach Cancer: Preoperative Staging and Monitoring of Response to Therapy
RadioGraphics,
January 1, 2006;
26(1):
143 - 156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Hawkins, S. M. Schuetze, J. E. Butrynski, J. G. Rajendran, C. B. Vernon, E. U. Conrad III, and J. F. Eary
[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors
J. Clin. Oncol.,
December 1, 2005;
23(34):
8828 - 8834.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol.,
November 1, 2005;
Supplement_28(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol.,
October 20, 2005;
23(30):
7445 - 7453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Westerterp, H. L. van Westreenen, J. B. Reitsma, O. S. Hoekstra, J. Stoker, P. Fockens, P. L. Jager, B. L. F. Van Eck-Smit, J. T. M. Plukker, J. J. B. van Lanschot, et al.
Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy--Systematic Review
Radiology,
September 1, 2005;
236(3):
841 - 851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril
Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET
J. Nucl. Med.,
July 1, 2005;
46(7):
1144 - 1150.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med.,
June 1, 2005;
46(6):
983 - 995.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res.,
April 15, 2005;
11(8):
2785 - 2808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Napieralski, K. Ott, M. Kremer, K. Specht, H. Vogelsang, K. Becker, M. Muller, F. Lordick, U. Fink, J. Rudiger Siewert, et al.
Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients
Clin. Cancer Res.,
April 15, 2005;
11(8):
3025 - 3031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest,
November 1, 2004;
126(5):
1656 - 1666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Swisher, M. Maish, J. J. Erasmus, A. M. Correa, J. A. Ajani, R. Bresalier, R. Komaki, H. Macapinlac, R. F. Munden, J. B. Putnam, et al.
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer
Ann. Thorac. Surg.,
October 1, 2004;
78(4):
1152 - 1160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Voelter, C. Schuhmacher, R. Busch, C. Peschel, J. R. Siewert, and F. Lordick
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer
Ann. Thorac. Surg.,
September 1, 2004;
78(3):
1037 - 1041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dimitrakopoulou-Strauss, L. G. Strauss, C. Burger, A. Ruhl, G. Irngartinger, W. Stremmel, and J. Rudi
Prognostic Aspects of 18F-FDG PET Kinetics in Patients with Metastatic Colorectal Carcinoma Receiving FOLFOX Chemotherapy
J. Nucl. Med.,
September 1, 2004;
45(9):
1480 - 1487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Shah and D. P. Kelsen
Editorial: Combined Modality Therapy of Esophageal Cancer: Changes in the Standard of Care?
Ann. Surg. Oncol.,
July 1, 2004;
11(7):
641 - 643.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Schoder, Y. E. Erdi, K. Chao, M. Gonen, S. M. Larson, and H. W.D. Yeung
Clinical Implications of Different Image Reconstruction Parameters for Interpretation of Whole-Body PET Studies in Cancer Patients
J. Nucl. Med.,
April 1, 2004;
45(4):
559 - 566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews
Multiple Management Modalities in Esophageal Cancer: Epidemiology, Presentation and Progression, Work-up, and Surgical Approaches
Oncologist,
April 1, 2004;
9(2):
137 - 146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Wieder, B. L.D.M. Brucher, F. Zimmermann, K. Becker, F. Lordick, A. Beer, M. Schwaiger, U. Fink, J. R. Siewert, H. J. Stein, et al.
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
J. Clin. Oncol.,
March 1, 2004;
22(5):
900 - 908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Kostakoglu and S. J. Goldsmith
PET in the Assessment of Therapy Response in Patients with Carcinoma of the Head and Neck and of the Esophagus
J. Nucl. Med.,
January 1, 2004;
45(1):
56 - 68.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ott, U. Fink, K. Becker, A. Stahl, H.-J. Dittler, R. Busch, H. Stein, F. Lordick, T. Link, M. Schwaiger, et al.
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
J. Clin. Oncol.,
December 15, 2003;
21(24):
4604 - 4610.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel
Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG
J. Nucl. Med.,
September 1, 2003;
44(9):
1426 - 1431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger
Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
J. Clin. Oncol.,
July 15, 2003;
21(14):
2651 - 2657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B B Chin and R L Wahl
18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies
Gut,
June 1, 2003;
52(90004):
iv23 - 29.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Chesnay, E. Babin, J. M. Constans, D. Agostini, A. Bequignon, A. Regeasse, F. Sobrio, and S. Moreau
Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome
J. Nucl. Med.,
April 1, 2003;
44(4):
526 - 532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Mac Manus, R. J. Hicks, J. P. Matthews, A. McKenzie, D. Rischin, E. K. Salminen, and D. L. Ball
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
April 1, 2003;
21(7):
1285 - 1292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Downey, T. Akhurst, D. Ilson, R. Ginsberg, M. S. Bains, M. Gonen, H. Koong, M. Gollub, B. D. Minsky, M. Zakowski, et al.
Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial
J. Clin. Oncol.,
February 1, 2003;
21(3):
428 - 432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Schwaiger
Functional imaging for assessment of therapy
Br. J. Radiol.,
November 1, 2002;
75(90009):
S67 - 73.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. R. Laking and P. M. Price
FDG-PET for response assessment: answers in search of questions
Ann. Onc.,
March 1, 2002;
13(3):
345 - 347.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Flamen, E. Van Cutsem, A. Lerut, J.-P. Cambier, K. Haustermans, G. Bormans, P. De Leyn, D. Van Raemdonck, W. De Wever, N. Ectors, et al.
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer
Ann. Onc.,
March 1, 2002;
13(3):
361 - 368.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|